⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Official Title: An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor

Study ID: NCT00967343

Study Description

Brief Summary: The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related, haploidentical donor enhances survival by improving the immune effect against infections while preventing graft-versus-host disease .

Detailed Description: Allogeneic stem cell transplantation is the treatment of choice for many patients with leukemia and other hematologic malignancies. However, a major limitation of this therapy is that for a significant number of patients no fully HLA-matched donor can be found. The application of partially HLA-matched (haploidentical) family donors, who are virtually always available, has some complications. If there is no T-cell add-back it increases the risk for life-threatening infections and disease relapse, while in case of T-cell add-back the risk for graft-versus-host disease is raised. Kiadis Pharma has developed a method to selectively deplete host alloreactive T-cells through photodynamic therapy, using TH9402 ex vivo. The donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) is administered to the patient 28-42 days after the stem cell transplant.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Ohio State University, Comprehesive Cancer Center, Columbus, Ohio, United States

Algemeen Ziekenhuis Sint-Jan, Brugge, , Belgium

Université Libre de Bruxelles - Institute Jules Bordet, Brussels, , Belgium

Universitair Ziekenhuis Gasthuisberg, Leuven, , Belgium

University of Liege - CHU Sart Tilman, Liege, , Belgium

HHSC, Henderson Hospital Site, Hamilton, Ontario, Canada

Ontario Cancer Institute / Princess Margaret Hospital, Toronto, Ontario, Canada

Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

Universitätsklinikum Freiburg, Medizinische UNI-Klinik, Freiburg, , Germany

Universitätsklinikums Schleswig-Holstein Campus Kiel, Kiel, , Germany

Universitätsklinikum Mainz, Mainz, , Germany

Universitätsklinikum Würzburg, Würzburg, , Germany

Perugia University, Perugia, , Italy

Academisch Ziekenhuis Maastricht, Maastricht, , Netherlands

Hammersmith Hospital, London, , United Kingdom

Contact Details

Name: Stephan Mielke, MD

Affiliation: Julius Maximilian University of Würzburg, Germany

Role: STUDY_CHAIR

Name: Denis-Claude Roy, MD

Affiliation: Maisonneuve-Rosemont Hospital, Montreal, Canada

Role: STUDY_CHAIR

Name: Andrea Velardi, MD

Affiliation: University Of Perugia

Role: PRINCIPAL_INVESTIGATOR

Name: Katy Rezvani, MD PhD

Affiliation: Hammersmith Hospital, London, United Kingdom

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: